|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | [[ICD#Implantation|Implantation of ICD]] |
| {{Atrophic vaginitis}}
| |
| {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}
| |
| | |
| ==Overview==
| |
| | |
| ==Medical Therpay==
| |
| Topical estrogen creams or tablets may be used vaginally. Oral or transdermal estrogen may be used. See '''Boxed Warning''' about estrogen therapy below.
| |
| | |
| Sexual activity is also helpful. A water-soluble vaginal lubricant may be useful.
| |
| | |
| === Boxed Warning ===
| |
| | |
| The labeling of estrogen-only products includes a [[black box warning|boxed warning]] that unopposed estrogen (without progestin) therapy increases the risk of [[endometrial cancer]].
| |
|
| |
| Based on a review of data from the WHI, on [[January 8]] [[2003]] the FDA changed the labeling of all estrogen and estrogen with progestin products for use by postmenopausal women to include a new boxed warning about cardiovascular and other risks. The estrogen-alone sub-study of the WHI reported an increased risk of [[stroke]] and [[deep vein thrombosis]] (DVT) in postmenopausal women 50 years of age or older and an increased risk of [[dementia]] in postmenopausal women 65 years of age or older using 0.625 mg of Premarin conjugated equine estrogens (CEE). The estrogen-plus-progestin substudy of the WHI reported an increased risk of [[myocardial infarction]], stroke, invasive [[breast cancer]], [[pulmonary emboli]] and DVT in postmenopausal women 50 years of age or older and an increased risk of dementia in postmenopausal women 65 years of age or older using 0.625 mg of CEE with 2.5 mg of the progestin [[medroxyprogesterone acetate]] (MPA).<ref name=fdanewlabel>{{cite web |author=FDA |title=FDA Approves New Labels for Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women Following Review of Women's Health Initiative Data |url=http://www.fda.gov/bbs/topics/NEWS/2003/NEW00863.html |date=1-8-2003 |accessdate=2006-09-20}}</ref><ref name="Medline">
| |
| {{cite web
| |
| | last =
| |
| | first =
| |
| | authorlink =
| |
| | coauthors =
| |
| | title = IMPORTANT WARNING
| |
| | work =
| |
| | publisher = MedlinePlus
| |
| | date =
| |
| | url = http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682922.html
| |
| | accessdate = 2006-09-18 }}
| |
| </ref><ref name="Times">
| |
| {{cite web
| |
| | last = Kolata
| |
| | first = Gina
| |
| | authorlink =
| |
| | coauthors =
| |
| | title = F.D.A. Orders Warning on All Estrogen Labels
| |
| | work =
| |
| | publisher = The New York Times
| |
| | date = 1-9-2003
| |
| | url = http://query.nytimes.com/gst/fullpage.html?sec=health&res=9C00E0DD103EF93AA35752C0A9659C8B63
| |
| | accessdate = 2006-09-18 }}
| |
| </ref>
| |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{WH}}
| |
| {{WS}}
| |
| | |
| [[Category:Overview complete]]
| |
| [[Category:Disease]]
| |
| [[Category:Gynecology]]
| |
| [[Category:Endocrinology]]
| |
| [[Category:Menopause]]
| |
| [[Category:Inflammations]]
| |